<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881032</url>
  </required_header>
  <id_info>
    <org_study_id>2020-004552-15</org_study_id>
    <nct_id>NCT04881032</nct_id>
  </id_info>
  <brief_title>AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma</brief_title>
  <acronym>NANO-GBM</acronym>
  <official_title>Phase I/II Study of AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Ministry of Health (PHRCI-19-060)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II clinical trial evaluating the association of AGuIX nanoparticles with&#xD;
      radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma.&#xD;
&#xD;
      The primary objectives of this study were to determine the recommended dose of AGuIX in&#xD;
      combination with radiotherapy and TMZ during the concomitant radiochemotherapy period (phase&#xD;
      I) and to estimate the efficacy of the combination radiochemotherapy + AGuIX (recommended&#xD;
      dose), measured by the 6-month progression-free survival rate (PFS) (phase II)&#xD;
&#xD;
      Three dose levels of intravenous AGuIX nanoparticles will be explored: 50 mg/kg, 75 mg/kg and&#xD;
      100 mg/kg.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1 : dose escalation Phase 2 : randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The recommended dose (phase I) of AGuIX in combination with TMZ and and radiotherapy during the radio-chemotherapy period</measure>
    <time_frame>during 11 weeks after the first injection of AGuIX</time_frame>
    <description>Only toxicities occurring during concomitant radiochemotherapy and the following 4 weeks will be considered for the evaluation of Dose Limiting Toxicity radiotherapy during the radio-chemotherapy period is defined as the highest dose tested in which the % of dose-limiting toxicities (DLT) is less than 33%. DLT is defined as any grade 3-4 toxicity according to the NCI CTCAE v5.0 classification, except alopecia, nausea, and vomiting which can be quickly controlled with appropriate measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month Progression Free Survival (PFS) rate (phase II)</measure>
    <time_frame>6 months from the start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Cmax of AGuIX</measure>
    <time_frame>Day 0 , Day 7, Day 14</time_frame>
    <description>maximal plasma concentration (Cmax) of AGuIX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Tmax of AGuIX</measure>
    <time_frame>Day 0 , Day 7, Day 14</time_frame>
    <description>time of maximal plasma concentration (Tmax) of AGuIX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic AUC of AGuIX</measure>
    <time_frame>Day 0 , Day 7, Day 14</time_frame>
    <description>Area Under the Curve (AUC) of AGuIX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic t1/2 of AGuIX</measure>
    <time_frame>Day 0 , Day 7, Day 14</time_frame>
    <description>pharmacokinetic term half-life (t1/2) of AGuIX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of AGuIX</measure>
    <time_frame>after the first and last injection of AGuIX, Week 0 and Day 14</time_frame>
    <description>measure of RMI contrast enhancement in tumor and healthy tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>from the start of treatment to death, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>from the start of treatment to progression, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (CTCAE criteria)</measure>
    <time_frame>from baseline to 30 days after treatment (concomitant and adjuvant treatment) (week 35)</time_frame>
    <description>according to NCI Common Toxicity Criteria for Adverse Effect (CTCAE) criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>AGuIX + chemoradiotherapy (radiotherapy + temozolomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>addition of AGuIX nanoparticles to standard radiotherapy and concomitant treatment by temozolomide (TMZ) for patients of phase I and patients randomized in experimental arm of phase II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemoradiotherapy (radiotherapy + temozolomide)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>standard of care : chemoradiotherapy (radiotherapy + temozolomide) for patients randomized in control arm of phase II</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polysiloxane Gd-Chelates based nanoparticles (AGuIX)</intervention_name>
    <description>Four intravenous injections of AGuIX will be delivered. Phase I : Three dose levels may be explored 50 mg/kg, 75 mg/kg and 100 mg/ kg. Phase II : recommended dose</description>
    <arm_group_label>AGuIX + chemoradiotherapy (radiotherapy + temozolomide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>60 Gy in 6 weeks</description>
    <arm_group_label>AGuIX + chemoradiotherapy (radiotherapy + temozolomide)</arm_group_label>
    <arm_group_label>chemoradiotherapy (radiotherapy + temozolomide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy.&#xD;
After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days .</description>
    <arm_group_label>AGuIX + chemoradiotherapy (radiotherapy + temozolomide)</arm_group_label>
    <arm_group_label>chemoradiotherapy (radiotherapy + temozolomide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of grade IV glioblastoma (biopsy or partial surgery)&#xD;
&#xD;
          -  Patient not operated or partial resection&#xD;
&#xD;
          -  KPS ≥ 70%&#xD;
&#xD;
          -  Age ≥ 18 years old and &lt;75 years old&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Platelets ≥ 100,000 / mm3&#xD;
&#xD;
          -  PNN ≥ 2000 / mm3&#xD;
&#xD;
          -  Hb ≥ 10 g / dL&#xD;
&#xD;
          -  Creatinine &lt;1.5 times the upper normal limit or clearance according to Cockcroft-Gault&#xD;
             ≥ 50 mL / min&#xD;
&#xD;
          -  Liver function (GGT, PAL, ASAT, ALAT, bilirubin) &lt;1.5 times the upper normal limit&#xD;
&#xD;
          -  For patients receiving treatment with corticosteroids, treatment with corticosteroids&#xD;
             must be at a stable or decreasing dose for at least 14 days before inclusion&#xD;
&#xD;
          -  Patient able to swallow and retain oral medication&#xD;
&#xD;
          -  Negative serum pregnancy test within 7 days before the first administration of&#xD;
             treatment for women&#xD;
&#xD;
          -  Women of childbearing potential and men whose partners are of childbearing potential&#xD;
             must agree to use, themselves or their partners, an approved method of contraception&#xD;
             throughout the treatment and at least 6 months after the last administration of study&#xD;
             treatment.&#xD;
&#xD;
          -  Obtaining signed informed consent from the patient&#xD;
&#xD;
          -  Patient affiliated to a social security regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior brain radiotherapy&#xD;
&#xD;
          -  prior chemotherapy (including implants containing carmustine (Gliadel®) or&#xD;
             immunotherapy (vaccination included)&#xD;
&#xD;
          -  Any contraindication to TMZ listed in the SPCs&#xD;
&#xD;
          -  History of major intestinal resection which may modify the absorption of oral drugs&#xD;
             according to the judgment of the investigator&#xD;
&#xD;
          -  Diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis)&#xD;
&#xD;
          -  Diarrhea ≥ grade 2 CTCAE (whatever the cause)&#xD;
&#xD;
          -  Current or recent treatment with another investigational drug or participation in&#xD;
             another therapeutic clinical trial (within 30 days of inclusion).&#xD;
&#xD;
          -  History of other cancer in the 5 years preceding inclusion, except for basal cell&#xD;
             carcinomas of the skin and in situ carcinomas of the cervix&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Contraindication to MRI or gadolinium injection&#xD;
&#xD;
          -  History of severe anaphylactic reactions due to the injection of gadolinium-based&#xD;
             contrast product (dotarem, etc.)&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  History of nephropathy&#xD;
&#xD;
          -  Psychological disorder or social or geographic reasons that may compromise medical&#xD;
             monitoring of the trial or compliance with treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliette Moreau, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie Thivat</last_name>
    <phone>0473278089</phone>
    <email>emilie.THIVAT@clermont.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Julian Biau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

